Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys

Journal of the National Cancer Institute

Volumn 100, Issue 21, 2008, Pages 1542-1551

  Sekeres, Mikkael A ^a   Schoonen, W Marieke ^b   Kantarjian, Hagop ^c   List, Alan ^d   Fryzek, Jon ^e   Paquette, Ronald ^f   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b AMGEN LTD   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e AMGEN INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AMIFOSTINE; ANAGRELIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; IMATINIB; LENALIDOMIDE; LEUPRORELIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RETINOIC ACID; TIOGUANINE; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE DURATION; ENVIRONMENTAL EXPOSURE; ERYTHROCYTE TRANSFUSION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PHYSICIAN; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; UNITED STATES;

ADULT; AGED; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CROSS-SECTIONAL STUDIES; ECONOMICS, PHARMACEUTICAL; ERYTHROPOIETIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEALTH CARE SURVEYS; HEALTH RESOURCES; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHYSICIANS; PROGNOSIS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 55749114037     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn349     Document Type: Article

References (26)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
2. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395.
3. Saarni MI, Linman JW. Preleukemia. The hematologic syndrome preceding acute leukemia. Am J Med. 1973;55(1):38-48.
4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
5. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109(9):1705-1714.
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
7. Malcovati L, Della Porta MG, Pascutto C, et al. The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome. ASH Annual Meeting Abstracts. Blood. 2005;106(11):791.
8. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510.
9. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group(IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
10. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-1046.
11. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
12. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456- 1465.
13. Golshayan AR, Jin T, Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol. 2007;137(2):125-132.
14. Sekeres MA, Fu AZ, Maciejewski JP, Golshayan AR, Kalaycio ME, Kattan MW. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer. 2007;109(6):1125-1132.
15. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
16. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579-585.
17. Chang C, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110(4):1379-1387.
18. Deeg HJ. Optimization of transplant regimens for patients with myelodysplastic syndrome(MDS). Hematology Am Soc Hematol Educ Program. 2005;167-173.
19. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82(2):358-367.
20. Iglesias Gallego M, Sastre Moral JL, Gayoso Diz P, Garcia Costa A, Ros Forteza S, Mayan Santos JM. Incidence and characteristics of myelodysplastic syndromes in Ourense(Spain) between 1994-1998. Haematologica. 2003;88(10):1197-1199.
21. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542.
22. Smart DR. Physician Characteristics and Distribution in the US. Chicago: AMA Bookshop; 2006.
23. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344-351.
24. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106(3):803-811.
25. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603.
26. Hurria A. Clinical trials in older adults with cancer: past and future. Oncology (Williston Park). 2007;21(3):351-358; discussion 363-364, 367.